to reduce their blood glucose levels glucagon-like peptide-1 (GLP-1) receptor agonists — these stimulate insulin secretion, inhibit the production of glucagon and slow down stomach emptying; they have ...
1 MacDonald, P. E. et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51, S434–442 (2002). 2 SGLT2 inhibitors and GLP-1 receptor agonists ...
while the inhibition of α-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions ...
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...
About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results